Clinical trial
Open Label Study of 908/RTV in Combination With Other PIs for the Treatment of…
NCT00144833 · GlaxoSmithKline, Industry · Terminated
Key facts
| NCT number | NCT00144833 |
|---|---|
| Title | Open Label Study of 908/RTV in Combination With Other PIs for the Treatment of Multi PI-Experienced HIV Subjects |
| Official title | A Phase III, Randomized, Controlled, Open-Label, Multicentre, Three Arm Study to Compare the Efficacy and Safety of a Dual-Boosted HIV-1 Protease Inhibitor Regimen of Fosamprenavir/Lopinavir/Ritonavir 1400mg/533mg/133mg Twice Daily and an Increased Dosage Regimen of FPV/RTV 1400mg/100mg BID Versus… |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | HIV-1 |
| Intervention type | Drug |
| Interventions | fosamprenavir/ritonavir (700mg/100mg BID), fosamprenavir/ritonavir (1400mg/100mg BID), fosamprenavir/lopinavir/ritonavir (1400mg/533mg/100mg BID) |
| Enrollment | 150 |
| Start date | Mar 1, 2005 |
| First posted | Sep 5, 2005 |
| Last update posted | Nov 12, 2007 |
| Countries | Australia, Belgium, Canada, France, Germany, Greece, Italy, Spain, United Kingdom |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: